An epidemiological study to describe symptom control and impact of gastroesophageal reflux disease
Study identifier:NIS-GRS-DUM-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An epidemiological, postmarketing observational study to describe symptom control and impact of gastroesophageal reflux disease (GERD) on patients’ daily life
Medical condition
GERD
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
1000
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 May 2010
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Patients with GERD | - |
Contacts
Investigators
Principal Investigator
Miodrag Krstić
Institute for Gastroenterology, Clinical Center of Serbia, Belgrade
